Evidence map›Paper›PMID 39001554›Full record

ReviewCancers2024

Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis.

Nicolas Girard, Mariam Besada, Basia Rogula, Stefano Lucherini, Lien Vo, Mohammad A Chaudhary, Sarah Goring, Greta Lozano-Ortega, Mia Tran, Nebibe Varol and 4 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Nicolas GirardDepartment of Medical Oncology, Institut Curie, 75005 Paris, France.
Mariam BesadaBroadstreet HEOR, Vancouver, BC V6A 1A4, Canada.
Basia RogulaBroadstreet HEOR, Vancouver, BC V6A 1A4, Canada.
Stefano LucheriniBristol Myers Squibb, Uxbridge UB8 1DH, UK.
Lien VoBristol Myers Squibb, Lawrenceville, NJ 08648, USA.
Mohammad A ChaudharyBristol Myers Squibb, Lawrenceville, NJ 08648, USA.
Sarah GoringBroadstreet HEOR, Vancouver, BC V6A 1A4, Canada.ORCID 0000-0001-8522-9354
Greta Lozano-OrtegaBroadstreet HEOR, Vancouver, BC V6A 1A4, Canada.ORCID 0000-0002-5378-0544
Mia TranBristol Myers Squibb, Lawrenceville, NJ 08648, USA.
Nebibe VarolBristol Myers Squibb, Uxbridge UB8 1DH, UK.
Nathalie WaserICON Plc, Burlington, ON L7N 3G2, Canada.ORCID 0000-0002-6880-8597
Winifred W YuICON Plc, Burlington, ON L7N 3G2, Canada.
Jay M LeeUCLA Health, Los Angeles, CA 90095, USA.
Jonathan SpicerDepartment of Thoracic Surgery, McGill University Health Center, Montreal, QC H3G 1A4, Canada.ORCID 0000-0003-2708-1309

Funding

Bristol Myers Squibb n/a
6 · The paper itself

Abstract

backgroundThis study aimed to estimate the relative efficacy of neoadjuvant nivolumab in combination with chemotherapy (neoNIVO + CT) compared to relevant treatments amongst resectable non-metastatic non-small-cell lung cancer (rNSCLC) patients.

methodsTreatment comparisons were based on a network meta-analysis (NMA) using randomized clinical trial data identified via systematic literature review (SLR). The outcomes of interest were event-free survival (EFS) and pathological complete response (pCR). NeoNIVO + CT was compared to neoadjuvant chemotherapy (neoCT), neoadjuvant chemoradiotherapy (neoCRT), adjuvant chemotherapy (adjCT), and surgery alone (S). Due to the potential for effect modification by stage, all-stage and stage-specific networks were considered. Fixed-effect (FE) and random-effects Bayesian NMA models were run (EFS = hazard ratios [HR]; pCR = odds ratios [OR]; 95% credible intervals [CrI]).

resultsSixty-one RCTs were identified (base case = 9 RCTs [

conclusionsThis NMA signals improved EFS and/or pCR of neoNIVO + CT relative to comparators among patients with rNSCLC.

Indexed as

network meta-analysisresectable non-small-cell lung cancersystematic literature review

Identifiers

PMID39001554
PMCPMC11240383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.